But based on the new kras findings, "You will likely see Erbitux moved up" and used sooner in patients with normal kras, predicts ImClone Chief Executive John H.
There are some studies that suggest harm in laboratory animals, but larger subsequent studies have failed to confirm any of these earlier findings of harm in lab animals, and there are no studies showing any harm in humans under normal consumer use.